United States

Prana Biotechnology Ltd (PRAN.OQ)

PRAN.OQ on NASDAQ Stock Exchange Capital Market

4:00pm EDT
Change (% chg)

$-0.03 (-1.20%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Prana Biotechnology Ltd announces that European Commission approves PBT2 orphan designation for Huntington's disease
Sunday, 31 May 2015 07:40pm EDT 

Prana Biotechnology Ltd:Says that the European Commission has approved orphan designation for PBT2 for treatment of Huntington's disease, stating that Prana has shown that PBT2 might be of significant benefit for patients with Huntington's disease.Says that approval was based on recommendation of positive opinion from European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP).  Full Article

Prana Biotechnology's PBT2 recommended for orphan designation in Europe
Monday, 27 Apr 2015 08:21pm EDT 

Prana Biotechnology:Says European Medicines Agency's Committee for Orphan Medicinal Products (COMP) has adopted positive opinion recommending designation of PBT2 for treatment of Huntington disease as orphan medicinal product to European Commission (EC).Says that following finalisation of relevant documents European Medicines Agency forwards opinion to EC for its decision on designation.  Full Article

More From Around the Web

BRIEF-Prana Biotechnology Ltd provides regulatory update for PBT2

* Prana Biotechnology Ltd - further advice from US Food and Drug Administration (FDA) on steps necessary to remove Partial Clinical Hold (PCH) on PBT2